763 related articles for article (PubMed ID: 23751441)
1. Clinical and laboratory significance of defective P2Y(12) pathway function in patients with myeloproliferative neoplasms: a pilot study.
Chang H; Shih LY; Michelson AD; Dunn P; Frelinger AL; Wang PN; Kuo MC; Lin TL; Wu JH; Tang TC
Acta Haematol; 2013; 130(3):181-7. PubMed ID: 23751441
[TBL] [Abstract][Full Text] [Related]
2. Comparison of VASP-phosphorylation assay to light-transmission aggregometry in assessing inhibition of the platelet ADP P2Y12 receptor.
Pampuch A; Cerletti C; de Gaetano G
Thromb Haemost; 2006 Dec; 96(6):767-73. PubMed ID: 17139371
[TBL] [Abstract][Full Text] [Related]
3. Comparison of conventional aggregometry with VASP for monitoring P2Y12-specific platelet inhibition.
Aradi D; Magyarlaki T; Tokés-Füzesi M; Rideg O; Vorobcsuk A; Komócsi A
Platelets; 2010; 21(7):563-70. PubMed ID: 20642320
[TBL] [Abstract][Full Text] [Related]
4. Comparison of a new ELISA assay with the flow cytometric assay for platelet vasodilator-associated stimulated phosphoprotein (VASP) phosphorylation in whole blood to assess P2Y(12) inhibition.
Jakubowski JA; Bourguet N; Boulay-Moine D; Sugidachi A; Yamaguchi S; Barragan P; Zhou C; Moulard M
Thromb Haemost; 2012 Feb; 107(2):388-95. PubMed ID: 22186965
[TBL] [Abstract][Full Text] [Related]
5. [Detection and clinical significance of JAK2 mutation in 412 patients with chronic myeloproliferative neoplasms].
Chao HY; Fan Z; Zhang R; Shen YM; Chen W; Fei HR; Zhu ZL; Feng YF; Chen ZX; Xue YQ
Zhonghua Zhong Liu Za Zhi; 2009 Jul; 31(7):510-4. PubMed ID: 19950698
[TBL] [Abstract][Full Text] [Related]
6. The role of adenosine diphosphate mediated platelet responsiveness for the stability of platelet integrity in citrated whole blood under ex vivo conditions.
Koessler J; Schwarz M; Weber K; Etzel J; Koessler A; Boeck M; Kobsar A
PLoS One; 2017; 12(11):e0188193. PubMed ID: 29155852
[TBL] [Abstract][Full Text] [Related]
7. Correlative study between the JAK2V617F mutation and thrombosis in patients with myeloproliferative neoplasm.
Li ZC; Fu HJ; Wang ZM; Yang S; Xu HZ
Genet Mol Res; 2016 Aug; 15(3):. PubMed ID: 27706633
[TBL] [Abstract][Full Text] [Related]
8. The clinical significance of JAK2V617F mutation for Philadelphia-negative chronic myeloproliferative neoplasms in patients with splanchnic vein thrombosis.
Yonal I; Pinarbası B; Hindilerden F; Hancer VS; Nalcaci M; Kaymakoglu S; Diz-Kucukkaya R
J Thromb Thrombolysis; 2012 Oct; 34(3):388-96. PubMed ID: 22569900
[TBL] [Abstract][Full Text] [Related]
9. Relationship between JAK2V617F mutation, allele burden and coagulation function in Ph-negative myeloproliferative neoplasms.
Hu L; Pu L; Ding Y; Li M; Cabanero M; Xie J; Zhou D; Yang D; Zhang C; Wang H; Zhai Z; Ru X; Li J; Xiong S
Hematology; 2017 Jul; 22(6):354-360. PubMed ID: 27976991
[TBL] [Abstract][Full Text] [Related]
10. Comparison of a new P2Y12 receptor specific platelet aggregation test with other laboratory methods in stroke patients on clopidogrel monotherapy.
Bagoly Z; Sarkady F; Magyar T; Kappelmayer J; Pongrácz E; Csiba L; Muszbek L
PLoS One; 2013; 8(7):e69417. PubMed ID: 23844259
[TBL] [Abstract][Full Text] [Related]
11. Effects of testosterone and 17β-oestradiol on expression of the G protein-coupled receptor P2Y12 in megakaryocytic DAMI cells.
Lee SJ; Kwon JA; Cho SA; Jarrar YB; Shin JG
Platelets; 2012; 23(8):579-85. PubMed ID: 22746349
[TBL] [Abstract][Full Text] [Related]
12. Thromboses and hemorrhages are common in MPN patients with high JAK2V617F allele burden.
Bertozzi I; Bogoni G; Biagetti G; Duner E; Lombardi AM; Fabris F; Randi ML
Ann Hematol; 2017 Aug; 96(8):1297-1302. PubMed ID: 28585070
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the VASP assay and platelet aggregometry in the evaluation of platelet P2Y12 receptor blockade.
Kuliczkowski W; Rychlik B; Chiżyński K; Watała C; Golański J
Pol Arch Med Wewn; 2011 Apr; 121(4):115-21. PubMed ID: 21532533
[TBL] [Abstract][Full Text] [Related]
14. Impact of JAK2V617F Mutation Burden on Disease Phenotype in Chinese Patients with JAK2V617F-positive Polycythemia Vera (PV) and Essential thrombocythemia (ET).
Zhao S; Zhang X; Xu Y; Feng Y; Sheng W; Cen J; Wu D; Han Y
Int J Med Sci; 2016; 13(1):85-91. PubMed ID: 26917989
[TBL] [Abstract][Full Text] [Related]
15. [Vascular myeloproliferative neoplasm with normal cell blood count: Exploration and medical management].
Fourgeaud C; El Nemer W; Michon Pasturel U; Bonhomme S; Brignier A; Lazareth I; Priollet P
J Mal Vasc; 2015 Dec; 40(6):350-8. PubMed ID: 26362408
[TBL] [Abstract][Full Text] [Related]
16. Platelets Express Activated P2Y
Hu L; Chang L; Zhang Y; Zhai L; Zhang S; Qi Z; Yan H; Yan Y; Luo X; Zhang S; Wang Y; Kunapuli SP; Ye H; Ding Z
Circulation; 2017 Aug; 136(9):817-833. PubMed ID: 28637879
[TBL] [Abstract][Full Text] [Related]
17. Prostacyclin receptor stimulation facilitates detection of human platelet P2Y(12) receptor inhibition by the PFA-100 system.
Kobsar AL; Koessler J; Rajkovic MS; Brunner KP; Steigerwald U; Walter U
Platelets; 2010; 21(2):112-6. PubMed ID: 20085435
[TBL] [Abstract][Full Text] [Related]
18. Identification of poor response to P2Y12 inhibitors in ACS patients with a new ELISA-based vasodilator-associated stimulated phosphoprotein (VASP) phosphorylation assay.
Abtan J; Silvain J; Kerneis M; O'Connor SA; Barthélémy O; Vignalou JB; Beygui F; Brugier D; Collet JP; Montalescot G
Thromb Haemost; 2013 Nov; 110(5):1055-64. PubMed ID: 23925438
[TBL] [Abstract][Full Text] [Related]
19. A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry.
Jakubowski JA; Payne CD; Li YG; Farid NA; Brandt JT; Small DS; Salazar DE; Winters KJ
Thromb Haemost; 2008 Jan; 99(1):215-22. PubMed ID: 18217157
[TBL] [Abstract][Full Text] [Related]
20. Inhibitory Effect of Flavonolignans on the P2Y12 Pathway in Blood Platelets.
Bijak M; Szelenberger R; Dziedzic A; Saluk-Bijak J
Molecules; 2018 Feb; 23(2):. PubMed ID: 29439388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
